Partial
Partially Aligned
Patient Risk:
Low
Summary
The evaluated content is largely about NDC identification/administrative mapping rather than FDA labeling statements. These claims are not supported or contradicted by the provided prescribing-information excerpts (Sections 1, 2, 3, 4, 5, 6, 8). One item (brand name equals active ingredient) is consistent with the label context provided, but most NDC-related statements cannot be verified against the supplied label text.
Category Scores
Accurate Statements
Sotyktu is the brand name for deucravacitinib.
The prompt-provided label context identifies SOTYKTU (deucravacitinib).
Unsupported Statements
In the U.S., an NDC (National Drug Code) identifies the exact drug and package size sold.
No NDC definition or description appears in the provided prescribing-information excerpts.
The current NDC for a specific Sotyktu strength (and package type) can be looked up on DrugPatentWatch.com.
No external database or look-up instruction is mentioned in the provided prescribing information.
DrugPatentWatch.com tracks drug identifiers and related information.
The provided prescribing information does not mention DrugPatentWatch.com or its functionality.
Sotyktu can have different NDCs depending on tablet strength.
The provided prescribing information excerpt does not discuss NDC multiplicity across strengths.
Sotyktu can have different NDCs depending on the number of tablets per bottle.
The provided prescribing information excerpt does not discuss NDC multiplicity across pack counts.
To avoid claim denials, an NDC should be matched to the exact strength of Sotyktu.
No payer/billing guidance, claim-denial avoidance, or NDC matching rationale is included in the provided prescribing information.
To avoid claim denials, an NDC should be matched to the exact package size/count.
The provided prescribing information does not include claim-denial or NDC matching guidance.
To avoid claim denials, an NDC should be matched to the dosage form (tablet vs other).
The provided prescribing information does not include claim-denial or NDC matching guidance by dosage form.
To avoid claim denials, an NDC should be matched to the manufacturer if more than one is listed.
The provided prescribing information does not include claim-denial or NDC matching guidance by manufacturer.
Contradictions
Important Omissions
Any label-supported NDC-specific instructions are absent from the provided excerpts; if an audit is intended to verify NDC usage, the relevant label sections containing NDC(s) were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims focus on NDC lookup/matching and billing denials; they do not directly assert dosing, safety, contraindications, or clinical use that would affect patient treatment based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are about NDC lookup, NDC variation, and avoiding claim denials, none of which are supported by the provided FDA prescribing-information excerpts.
Suggested Improvement
Limit statements to label-supported facts (e.g., name/active ingredient) and remove or qualify NDC/billing assertions unless the exact label section containing NDC details (and any relevant instructions) is provided.